Human neutralizing monoclonal antibodies to respiratory syncytial virus

   
   

A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.

Un metodo per fornire immmunotherapy passivo alla malattia sinciziale respiratoria del virus (RSV) in un ospite รจ rilevato. Il metodo include l'amministrazione ad un ospite un frammento monoclonal umano di Fab dell'anticorpo che neutralizza sia il sottogruppo antigenico A che il sottogruppo B di virus sinciziale respiratorio (RSV), o dell'anticorpo monoclonal che contiene il frammento.

 
Web www.patentalert.com

< Use of parapox PP30 protein to modify immune responses to administered antigens

< Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2

> Use of parapox B2L protein to modify immune responses to administered antigens

> Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences

~ 00100